The earnings call emphasizes significant progress in clinical trials for Avexitide and AMX0035, alongside financial stability with reduced expenses. However, challenges remain in cash management and market education. Overall, the highlights in drug development and financial management outweigh the concerns, indicating a positive outlook.

Company Guidance -

Q3 2025

During the Amylyx Pharmaceuticals Second Quarter 2025 Earnings Conference Call, the company provided guidance on multiple clinical and financial metrics. The company is advancing its lead asset, Avexitide, through the pivotal Phase III LUCIDITY trial for post-bariatric hypoglycemia (PBH) and expects to complete recruitment by the end of 2025, with top-line data anticipated in the first half of 2026. For Avexitide, a commercial launch is planned for 2027 if approved. Their pipeline also includes AMX0035, with top-line data from the Phase IIb ORION trial in progressive supranuclear palsy (PSP) expected this quarter, and AMX0114, which received Fast Track designation, with early cohort data expected by year-end. Financially, Amylyx ended the second quarter with a cash position of $180.8 million and anticipates a cash runway extending through the end of 2026, supporting its clinical milestones and early commercial preparations. Total operating expenses for the quarter were $42.9 million, with research and development expenses at $27.2 million, primarily driven by increased spending on Avexitide and AMX0035.

Avexitide Advancements in Phase III LUCIDITY Trial

Successfully dosed first participant in pivotal Phase III LUCIDITY trial for post-bariatric hypoglycemia (PBH). Recruitment expected to complete by year-end, with anticipated commercial launch in 2027 if approved.

Positive Developments in AMX0035 Trials

Long-term Week 48 data for AMX0035 in Wolfram syndrome showed sustained stabilization or improvement. Phase IIb data from PSP trials expected this quarter to inform Phase III decisions.

Financial Stability and Reduced Operating Expenses

Cash position of $180.8 million, with operating expenses down 43% from the same period in 2024. Cash runway expected to last through the end of 2026.

FDA Fast Track Designation for AMX0114

The FDA granted Fast Track designation to AMX0114 for ALS, allowing for more frequent interactions with the FDA and potential for expedited review.

Significant Reduction in Hypoglycemic Events with Avexitide

Avexitide led to a 64% reduction in hypoglycemic events in Phase II trials, with more than half of participants experiencing no Level 2 or Level 3 hypoglycemic events during treatment.

Amylyx Pharmaceuticals Inc (AMLX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AMLX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.46 / -	-1.07	―	―	―
Aug 07, 2025	2025 (Q2)	-0.44 / -0.46	-1.07	57.01% (+0.61)	―
May 08, 2025	2025 (Q1)	-0.47 / -0.42	-1.75	76.00% (+1.33)	―
Mar 04, 2025	2024 (Q4)	-0.52 / -0.55	0.07	-885.71% (-0.62)	―
Nov 07, 2024	2024 (Q3)	-0.70 / -1.07	0.3	-456.67% (-1.37)	―
Aug 08, 2024	2024 (Q2)	-0.73 / -1.07	0.31	-445.16% (-1.38)	―
May 09, 2024	2024 (Q1)	>-0.01 / -1.75	0.02	-8850.00% (-1.77)	―
Feb 22, 2024	2023 (Q4)	0.23 / 0.07	-0.65	110.77% (+0.72)	―
Nov 09, 2023	2023 (Q3)	0.44 / 0.30	-0.92	132.61% (+1.22)	―
Aug 10, 2023	2023 (Q2)	0.19 / 0.31	-0.93	133.33% (+1.24)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AMLX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$8.19	$7.84	-4.27%
May 08, 2025	$4.87	$4.58	-5.95%
Mar 04, 2025	$3.00	$3.01	+0.33%
Nov 07, 2024	$6.22	$6.54	+5.14%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.